Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(mometasone inhalation )
159 results
  • As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say? [Review]
    Drugs. 2019 Nov; 79(16):1729-1737.Domingo C, Rello J, Sogo A
  • For the last three decades, the guidelines for asthma management have supported a stepwise therapeutic approach, based on the administration of controller medications (especially inhaled corticosteroids) complemented by on-demand use of rescue medication. Classically, the rescue medication recommended comprised short-acting β agonists (SABA). Some years ago, the use of Symbicort Maintenance and R…
  • Inhaled steroids with and without regular formoterol for asthma: serious adverse events. [Journal Article]
    Cochrane Database Syst Rev. 2019 09 25; 9:CD006924.Janjua S, Schmidt S, … Cates CJ
  • CONCLUSIONS: We did not find a difference in the risk of death (all-cause or asthma-related) in adults taking combined formoterol and ICS versus ICS alone (moderate- to low-certainty evidence). No deaths were reported in children and adolescents. The risk of dying when taking either treatment was very low, but we cannot be certain if there is a difference in mortality when taking additional formoterol to ICS (low-certainty evidence).We did not find a difference in the risk of non-fatal SAEs of any cause in adults (high-certainty evidence). A previous version of the review had shown a lower risk of asthma-related SAEs in adults taking combined formoterol and ICS; however, inclusion of new studies no longer shows a difference between treatments (moderate-certainty evidence).The reported number of children and adolescents with SAEs was small, so uncertainty remains in this age group.We included results from large studies mandated by the FDA. Clinical decisions and information provided to patients regarding regular use of formoterol and ICS need to take into account the balance between known symptomatic benefits of formoterol and ICS versus the remaining degree of uncertainty associated with its potential harmful effects.
  • Inhalation Aerosol Therapy in the Treatment of Chronic Rhinosinusitis: A Prospective Randomized Study. [Journal Article]
    J Clin Pharmacol. 2019 12; 59(12):1648-1655.Velepič M, Manestar D, … Braut T
  • The purpose of the study was to compare treatment of chronic rhinosinusitis (CRS) with topical glucocorticoids and saline irrigation versus aerosol inhalation therapy. Patients diagnosed with CRS were randomly divided into 2 groups. In the first group, patients were treated with topical glucocorticoids (mometasone furoate, 100 µg in each nostril once daily) and saline irrigation (150 mL twice a d…
  • Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. [Randomized Controlled Trial]
    N Engl J Med. 2019 05 23; 380(21):2009-2019.Lazarus SC, Krishnan JA, … National Heart, Lung, and Blood Institute AsthmaNet
  • CONCLUSIONS: The majority of patients with mild, persistent asthma had a low sputum eosinophil level and had no significant difference in their response to either mometasone or tiotropium as compared with placebo. These data provide equipoise for a clinically directive trial to compare an inhaled glucocorticoid with other treatments in patients with a low eosinophil level. (Funded by the National Heart, Lung, and Blood Institute; SIENA number, NCT02066298.).
  • Repurposing drugs as inhaled therapies in asthma. [Review]
    Adv Drug Deliv Rev. 2018 08; 133:19-33.Anderson SD
  • For the first 40 years of the 20th century treatment for asthma occurred in response to an asthma attack. The treatments were given by injection or orally and included the adrenergic agonists adrenalin/epinephrine and ephedrine and a phosphodiesterase inhibitor theophylline. Epinephrine became available as an aerosol in 1930. After 1945, isoprenaline, a non-selective beta agonist, became availabl…
  • Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma. [Meta-Analysis]
    Allergy Asthma Proc. 2016 Nov; 37(6):125-139.Nguyen VQ, Ulrik CS
  • CONCLUSIONS: In adults with severe asthma, several corticosteroid-sparing interventions were shown to be effective in reducing systemic steroid exposure, not least in studies of add-on biologic therapy. However, based on the available studies, ciclesonide, based on the low potential for systemic effect, especially seems to be a good candidate for reducing steroid exposure in these patients before possible initiation of biologic therapy.
  • Ex vivo Cutaneous Bioavailability of Topical Mometasone Furoate in an O/W Preparation. [Journal Article]
    Skin Pharmacol Physiol. 2016; 29(5):273-279.Wohlrab J, Neubert RH, … Michael J
  • Mometasone furoate (MMF) is a modern glucocorticoid of the 4th generation, which has been proven not only for inhalation but also for cutaneous treatment. Due to its lipophilic character, it is mainly used in ointments and creams with an outer lipophilic phase (W/O type). However, this study investigated the cutaneous cytotoxicology of MMF and tried to characterize its pharmacokinetic effects on …
  • Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler. [Journal Article]
    Biol Pharm Bull. 2016; 39(10):1576-1580.Yokoyama H, Ito K, … Yamada Y
  • The aim of this study was to establish an appropriate inhalation method with a mometasone furoate dry powder inhaler (MF-DPI). Utilizing a tone-based inhalation training device, we investigated the maximum peak inspiratory flow rate time (Tmax PIFR) and peak inspiratory flow rate (PIFR) to determine whether either had an influence on lung deposition with use of an MF-DPI. A low tone indicated a P…
  • Radioactive Merano SPA Treatment for Allergic Rhinitis Therapy. [Journal Article]
    Int J Otolaryngol. 2016; 2016:2801913.Passali D, Gabelli G, … Bellussi LM
  • Allergic rhinitis is a common nasal disorder with a high impact on quality of life, high social costs in therapies, and a natural development towards asthma. Pharmacological therapy is based on several genres of medications, of which intranasal corticosteroids are currently the most widespread. Thermal water treatment has traditionally been used as adjunctive treatment for chronic rhinitis and si…
  • Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. [Review]
    Cochrane Database Syst Rev. 2015 May 21Kew KM, Beggs S, Ahmad S
  • CONCLUSIONS: There is currently no evidence from randomised trials to inform the discontinuation of LABAs in children once asthma control is achieved with ICS plus LABA. It is disappointing that such an important issue has not been studied, and a randomised double-blind trial recruiting children who are controlled on ICS plus LABA is warranted. The study should be large enough to assess children of different ages, and to measure the important safety and efficacy outcomes suggested in this review over at least six months.The only randomised evidence for stopping LABA has been conducted in adults; it will be summarised in a separate review.
New Search Next